title: MET as a target in papillary renal cell carcinoma.
abstract: The biology underlying papillary renal cell carcinoma (pRCC) is largely unknown, and no specific therapies have been developed for advanced disease. The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors.
authors.affiliation: Authors' Affiliations: Dana-Farber Cancer Institute;
authors.forename: André P
authors.initials: AP
authors.lastname: Fay
authors.affiliation: Authors' Affiliations: Dana-Farber Cancer Institute; Brigham and Women's Hospital; and Harvard Medical School, Boston, Massachusetts.
authors.forename: Sabina
authors.initials: S
authors.lastname: Signoretti
authors.affiliation: Authors' Affiliations: Dana-Farber Cancer Institute; Brigham and Women's Hospital; and Harvard Medical School, Boston, Massachusetts toni_choueiri@dfci.harvard.edu.
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
mesh_terms: D002291:Carcinoma, Papillary / Q000235:genetics*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000473:pathology*; D008297:Male; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*
chemical_list: D019859:Proto-Oncogene Proteins c-met